Related Articles
Collaborating on Triplet Therapy for Metastatic Hormone-Sensitive Prostate Cancer – Daniel Saltzstein
Zach Klaassen converses with Daniel Saltzstein about the collaborative approach in treating metastatic hormone-sensitive prostate cancer with triplet therapy. Dr. Saltzstein describes their unique setup…
AUA 2024: Prostate-Specific Antigen Dynamics from the Phase 3 EMBARK Trial: A Post Hoc Analysis
AUA 2024: Prostate-Specific Antigen Dynamics, EMBARK Trial, enzalutamide, leuprolide, enzalutamide plus leuprolide combination therapy.
AUA 2024: Differences in Barriers and Facilitators to First-Line Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer Between Urologists and Oncologists: A Sub-Analysis of the IMPLEMENT Study
AUA 2024, metastatic castration-sensitive prostate cancer (mCSPC), IMPLEMENT study, IMPLEMENT study barriers, IMPLEMENT study facilitators, IMPLEMENT study barrier to facilitator, androgen-deprivation therapy (ADT).
AUA 2024: Pivotal Results from BOND-003: A Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
AUA 2024 BOND-003, intravesical cretostimogene grenadenorepvec for the treatment of high risk BCG-unresponsive non-muscle invasive bladder cancer, Coxsackie Adenovirus Receptor (CAR).
AUA 2024: Analyzing the Percentage of Positive 68Ga-PSMA-PET/CT Scans Based on PSA Ranges Across Distinct Indications for the Scan
AUA 2024, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), 68Ga-PSMA-PET/CT, Positive 68Ga-PSMA-PET/CT Scans Based on PSA Ranges.
Breaking Paradigms: BOND-003’s Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer – Mark Tyson
Mark Tyson presents results from the BOND-003 study, evaluating the efficacy of cretostimogene grenadenorepvec monotherapy in treating BCG-unresponsive non-muscle-invasive bladder cancer. Cretostimogene, an oncolytic adenovirus,…
AUA 2024: State-of-the-Art Lecture: Prostate Cancer Screening in High-risk Groups
AUA 2024 prostate cancer screening in high risk groups, cancer related death among males, prostate cancer incidence by race, risk of prostate cancer, USPSTF recommendations.
AUA 2024: SOPHIA Study: The New Artificial Urinary Sphincter UroActive™: Results of the First in Man Study at 6 Months Post-Activation
AUA 2024 SOPHIA study, new artificial urinary sphincter UroActive™, first results of the SOPHIA study, UroActive™, stress urinary incontinence surgery, Quality of life questionnaires.
AUA 2024: Accuracy of FDG-PET Scan in Primary Testicular Seminoma: Analysis from SEMS Trial
AUA 2024 analysis from the SEMS trial, accuracy of FDG-PET scan in primary testicular seminoma, Surgery in Early Metastatic Seminoma, PET scans to detect retroperitoneal…
AUA 2024: Propensity-Matched Analysis of Open Versus Robotic Primary Retroperitoneal Lymph Node Dissection for CS II Testicular Cancer
AUA 2024 open versus robotic primary retroperitoneal lymph node dissection (RPLND), CS II testicular cancer, minimally invasive techniques, Kaplan-Meier product-limit method.